Skip to main content

View full-text article in PMC

. 2021 Mar 26;21:324. doi: 10.1186/s12885-021-08050-w

Table 2.

Drug-drug Interaction Prevalence

Primary analysis
	Study ID	Protocol: Exclude	Protocol: Avoid	Protocol: Caution	Lexicomp®	Clinically Relevant
DDI At Study Enrollment	S0711	12.0% (10/83)	6.0% (5/83)	2.4% (2/83)	55.4% (46/83)	12.0% (10/83)
DDI At Study Enrollment	S0528	11.9% (10/84)	3.6% (3/84)	6.0% (5/84)	2.4% (2/84)	2.4% (2/84)
DDI Added During Study	S0711	13.3% (11/83)	6.0% (5/83)	2.4% (2/83)	20.5% (17/83)	13.3% (11/83)
DDI Added During Study	S0528	3.6% (3/84)	0.0% (0/84)	0.0% (0/84)	0.0% (0/84)	0.0% (0/84)
Secondary analysis
	Study ID	Protocol: Exclude	Protocol: Avoid	Protocol: Caution	Lexicomp®	Clinically Relevant
DDI At Study Enrollment	S0711	22.9% (19/83)	6.0% (5/83)	2.4% (2/83)	55.4% (46/83)	22.9% (19/83)
DDI At Study Enrollment	S0528	11.9% (10/84)	3.6% (3/84)	6.0% (5/84)	2.4% (2/84)	2.4% (2/84)
DDI Added During Study	S0711	15.7% (13/83)	6.0% (5/83)	2.4% (2/83)	20.5% (17/83)	15.7% (13/83)
DDI Added During Study	S0528	6.0% (5/84)	0.0% (0/84)	0.0% (0/84)	0.0% (0/84)	0.0% (0/84)

DDI drug-drug interaction